CLEAR EYES NATURAL TEARS MILD DRY EYES

Compare CLEAR EYES NATURAL TEARS MILD DRY EYES  to:
Compare
Compare

Generic Name for CLEAR EYES NATURAL TEARS MILD DRY EYES

Polyvinyl alcohol 0.5%, povidone 0.6%; oph. soln; contains benzalkonium chloride.

Legal Classification:

OTC

Pharmacological Class for CLEAR EYES NATURAL TEARS MILD DRY EYES

Ocular lubricants.

Manufacturer of CLEAR EYES NATURAL TEARS MILD DRY EYES

Prestige Brands, Inc.

Indications for CLEAR EYES NATURAL TEARS MILD DRY EYES

Dry eye.

Adults and Children:

Instill 1–2 drops in affected eye(s) as needed.

Also:

Precautions for CLEAR EYES NATURAL TEARS MILD DRY EYES

Discontinue if eye pain, vision changes, redness or irritation persist beyond 72 hours or worsen.

Adverse Reactions for CLEAR EYES NATURAL TEARS MILD DRY EYES

Blurred vision (liq.gels).

How is CLEAR EYES NATURAL TEARS MILD DRY EYES supplied?

Tears Mild—0.5oz
Tears Moderate to Severe—0.5oz
Tears Sensitive—32 (0.02oz/single-use dispensers)
PM Tears Nighttime—0.12oz

Related Disease:

Dry eye~ocular lubricants

Related Resources

Phase 2 study of RX-10045 for the treatment of chronic dry eye syndrome

August 24, 2009

Resolvyx Pharmaceuticals announced positive data from its Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

Restasis available in 60-count package size

May 04, 2009

Restasis (cyclosporine 0.05%, from Allergan) ophthalmic emulsion is now available in a 60-count package (two trays of 30 vials) that provides patients with a 30-day supply.

Lacrisert now available from Aton

October 29, 2008

Aton Pharma has launched Lacrisert (hydroxypropyl cellulose ophthalmic insert) for the treatment of moderate-to-severe dry eye syndromes.

FDA withdraws unapproved ophthalmic balanced salt solutions

September 23, 2008

The FDA has ordered manufacturers of unapproved ophthalmic balanced salt solutions (BSS) to discontinue production.

Silenor approved for insomnia

March 18, 2010

The FDA has approved Silenor (doxepin tablets, from Somaxon Pharmaceuticals) for the treatment of insomnia characterized by difficulty with sleep maintenance.